Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
42 studies found for:    "Anthrax"
Show Display Options
RSS Create an RSS feed from your search for:
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)
Condition: Anthrax
Interventions: Biological: Anthrax Immune Globulin Intravenous (AIGIV);   Biological: Gamunex
2 Completed Plasmapheresis of Anthrax-Vaccinated Subjects for Production of Anthrax Immune Globulin
Condition: Anthrax
Intervention: Drug: Anthrax Immune Globulin
3 Completed Anthrax-rPA: Safety, Tolerability, Immunogenicity
Condition: Anthrax
Intervention: Biological: Recombinant Protective Antigen, Anthrax Vaccine Adsorbed
4 Completed A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults
Condition: Anthrax
Interventions: Biological: Anthrax;   Biological: Alhdryogel or PBS
5 Recruiting Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients
Condition: Anthrax
6 Active, not recruiting A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines
Condition: Anthrax Infection
Interventions: Biological: AVA;   Biological: Ad4-PA-1;   Biological: Ad4-PA-GPI-1
7 Completed Anthrax Vaccine Clinical Trials
Condition: Anthrax
Interventions: Drug: Anthrax Vaccine;   Procedure: Blood Chemistry;   Procedure: Hematology;   Procedure: Urinalysis
8 Completed Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum
Condition: Symptoms of Inhalational Anthrax
Intervention: Biological: NP-015
9 Completed Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed
Condition: Bacillus Anthracis (Anthrax)
Interventions: Biological: AVA;   Biological: rPA vaccine containing alhydrogel
10 Active, not recruiting A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels
Condition: Anthrax
Interventions: Biological: AV7909;   Biological: BioThrax
11 Completed Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine
Condition: Prevention of Anthrax Infection
Intervention: Biological: rPA102 Vaccine
12 Completed Efficacy and Safety of Anthrax Vaccine, GC1109
Condition: Anthrax
Interventions: Biological: Low-dose GC1109;   Biological: High-dose GC1109;   Biological: Low-dose Placebo;   Biological: High-dose Placebo
13 Completed Monoclonal Antibody for Treatment of Inhalation Anthrax
Condition: Bacillus Anthracis (Anthrax)
Interventions: Drug: Ciprofloxacin 500 mg;   Drug: ETI-204 (Anthim)
14 Completed
Has Results
Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults
Condition: Bacillus Anthracis (Anthrax) Infection
Interventions: Biological: BioThrax;   Biological: AV7909 Formulation 1;   Biological: AV7909 Formulation 2;   Biological: AV7909 Formulation 3;   Biological: AV7909 Formulation 4;   Drug: Control
15 Terminated UMD rPA Regimen Trial in Adults
Condition: Bacillus Anthracis (Anthrax)
Interventions: Biological: Anthrax vaccine absorbed made from Bacillus anthracis (AVA);   Biological: Recombinant protein antigen (rPA) made from Bacillus anthrax;   Biological: Recombinant protein antigen (rPA) made from Escherichia coli
16 Completed
Has Results
Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule
Condition: Bacillus Anthracis (Anthrax)
Intervention: Biological: BioThrax®
17 Completed Phase II Study of Range and Schedule of rPA Doses
Condition: Prevention of Bacillus Anthracis (Anthrax) Infection
Intervention: Biological: rPA vaccine containing alhydrogel
18 Recruiting Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
Conditions: Ischemic Stroke;   Malignant Edema
Intervention: Drug: RP-1127 (Glyburide for Injection)
19 Completed Trial of rPA-102 Vaccine in Healthy Adult Volunteers
Condition: Anthrax
Intervention: Biological: rPA102
20 Active, not recruiting A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109
Condition: Anthrax
Interventions: Biological: rPA vaccine containing alhydrogel 1.0 mL;   Drug: Normal Saline;   Biological: rPA vaccine containing alhydrogel 0.5 mL;   Biological: rPA vaccine containing alhydrogel 0.3 mL

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years